Hemophilia A: Innovative Treatment Approaches for Patients with Inhibitors

We are exploring various treatment methods for individuals with Hemophilia A who have inhibitors. The goal is to see how well these treatments reduce bleeding and improve health outcomes.

>2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesInjectionHematology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Feiba
Feiba is a medicine used to help control and stop bleeding in people with hemophilia who don't respond to standard treatments.
Hemlibra
Hemlibra is a medicine used to prevent or reduce bleeding in people with hemophilia A.
Human Coagulation Factor Viii (Inhibitor Bypassing Fraction) Baxalta
Baxalta's inhibitor-bypassing factor is used to control bleeding in people with hemophilia whose bodies have developed antibodies that make standard treatments ineffective.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Emicizumab
Emicizumab is a substance that helps prevent bleeding in people with hemophilia A by mimicking factor VIII to promote blood clotting.
Eptacog Alfa (Activated)
Eptacog alfa (activated) is a substance that helps blood clot to control bleeding in people with certain bleeding disorders.
Eptacog Beta (Activated)
Eptacog beta (activated) is a substance that helps blood clot to stop bleeding in people with certain severe bleeding disorders like hemophilia with inhibitors.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Wilate
Cevenfacta
Hemlibra

What similar medicines might you know?

Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.

Alphanate
Beriate
Beriate 1000

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Specialized Hospital For Active Treatment Of Hematological Diseases EAD
Clinic of Pediatric Hematology for treatment of children with benign hematological diseases 0-18y
Sofia, Bulgaria
University Hospital Centre Zagreb
Internal medicine
Zagreb, Croatia
HUS-Yhtymae
New Children’s Hospital
Helsinki, Finland
Sponsor: HZRM Haemophilie-Zentrum Rhein Main GmbH
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.